Literature DB >> 15923436

Hormonotherapy of advanced prostate cancer.

P Pronzato1, M Rondini.   

Abstract

More than two decades of studies on hormonal treatment of Prostate Cancer are briefly reviewed. Recent American Society of Clinical Oncology recommendations have pointed the major issues faced in randomized clinical trials and meta-analyses. Androgen ablation remains the mainstay of treatment for advanced stages, while Docetaxel based chemotherapy is becoming the standard in hormonorefractory tumors and targeted therapies are approaching.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15923436     DOI： 10.1093/annonc/mdi913

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  7 in total

1.  Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.

Authors:  Tong Sun; Gwo-Shu Mary Lee; Lillian Werner; Mark Pomerantz; William K Oh; Philip W Kantoff; Matthew L Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

2.  Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer.

Authors:  Jiunn-Bey Pao; Ying-Pi Yang; Chun-Nung Huang; Shu-Pin Huang; Tzyh-Chyuan Hour; Ta-Yuan Chang; Yu-Hsuan Lan; Te-Ling Lu; Hong-Zin Lee; Shin-Hun Juang; Chao-Yuan Huang; Bo-Ying Bao
Journal:  World J Urol       Date:  2011-12-23       Impact factor: 4.226

3.  IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.

Authors:  Andreia Azevedo; Virginia Cunha; Ana Luisa Teixeira; Rui Medeiros
Journal:  World J Clin Oncol       Date:  2011-12-10

Review 4.  Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.

Authors:  Shinichi Sakamoto; A Jacqueline Ryan; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2008-02-15       Impact factor: 4.429

5.  Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).

Authors:  Supriya Perambakam; Hui Xie; Seby Edassery; David J Peace
Journal:  Clin Dev Immunol       Date:  2011-01-05

6.  Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo.

Authors:  Guangyao Lv; Dengjun Sun; Jingwen Zhang; Xiaoxia Xie; Xiaoqiong Wu; Weishuo Fang; Jingwei Tian; Chunhong Yan; Hongbo Wang; Fenghua Fu
Journal:  Acta Pharm Sin B       Date:  2016-07-07       Impact factor: 11.413

7.  METTL3-mediated m6A modification of KIF3C-mRNA promotes prostate cancer progression and is negatively regulated by miR-320d.

Authors:  Honggui Ma; Facai Zhang; Quliang Zhong; Jianquan Hou
Journal:  Aging (Albany NY)       Date:  2021-09-19       Impact factor: 5.682
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.